title: Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
abstract: Laron syndrome (LS, congenital primary GH insensitivity) is caused by deletions or mutations in the GH receptor gene, resulting in an inability to generate insulin-like growth factor-I (IGF-I). If untreated, the deficiency of IGF-I results in severe dwarfism, as well as skeletal and muscular underdevelopment. The only treatment is the daily administration of recombinant IGF-I. This review summarizes the present experience by several groups worldwide. The main conclusions are: A. The one or two injections regimen result in the same growth velocity; B. The growth velocity obtained with IGF-I administration is smaller than that observed with hGH in children with congenital isolated GH deficiency; C. Overdosage of IGF-I causes a series of adverse effects which can be avoided by carefully monitoring the serum IGF-I and GH levels.
authors: Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Sackler Faculty of Medicine, Tel Aviv University, Israel. laronz@clalit.org.il
authors: Zvi
authors: Z
authors: Laron
mesh_terms: D002648:Child; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D046150:Laron Syndrome / Q000188:drug therapy*
chemical_list: D007334:Insulin-Like Growth Factor I